Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.61 |
| ▸ | DUT | P33316 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078688 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2762704 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6060488 | 1.00 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL15866629 | 0.91 | DUT (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21089328 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL10521044 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL8909630 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL19861744 | 0.90 | DUT (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL24782135 | 0.89 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21089723 | 0.89 | DUT (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158431-A1 | COMPOSITIONS AND COMPOUNDS FOR CO-DELIVERY OF URIDINE AND KETOLEUCINE | WELLSTAT THERAPEUTICS CORPORATION | 2024-05-16 | — | — | US | disclosed |
| CN-117529326-A | Compositions and compounds for co-delivery of uridine and ketoleucine | 制药五有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4294405-A1 | COMPOSITIONS AND COMPOUNDS FOR CO-DELIVERY OF URIDINE AND KETOLEUCINE | Pharma Cinq, LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-109641931-B | Method for synthesizing ribonucleic acid H-phosphate monomer and oligonucleotide synthesis using the same | 基因设计有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022177740-A1 | COMPOSITIONS AND COMPOUNDS FOR CO-DELIVERY OF URIDINE AND KETOLEUCINE | WELLSTAT THERAPEUTICS CORPORATION (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11174279-B2 | Method for synthesizing ribonucleic acid H-phosphonate monomer, and oligonucleotide synthesis in which said monomer is used | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20200331945-A1 | METHOD FOR SYNTHESIZING RIBONUCLEIC ACID H-PHOSPHONATE MONOMER, AND OLIGONUCLEOTIDE SYNTHESIS IN WHICH SAID MONOMER IS USED | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-10-22 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3473637-A1 | METHOD FOR SYNTHESIZING RIBONUCLEIC ACID H-PHOSPHONATE MONOMER, AND OLIGONUCLEOTIDE SYNTHESIS IN WHICH SAID MONOMER IS USED | Genedesign, Inc. (JP) | 2019-04-24 | — | — | EP | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-5455339-A | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | SLC28A1 601/4885SLC28A2 474/4885SLC29A1 324/4885 |
| US-20200331945-A1 | METHOD FOR SYNTHESIZING RIBONUCLEIC ACID H-PHOSPHONATE MONOMER, AND OLIGONUCLEOTIDE SYNTHESIS IN WHICH SAID MONOMER IS USED | RNGTT, RNASEL, NSUN3 | SLC28A1 1597/4885SLC28A2 1562/4885SLC29A1 551/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | SLC28A1 601/4885SLC28A2 474/4885SLC29A1 324/4885 |
| US-11174279-B2 | Method for synthesizing ribonucleic acid H-phosphonate monomer, and oligonucleotide synthesis in which said monomer is used | RNGTT, RNASEL, NSUN3 | SLC28A1 1597/4885SLC28A2 1562/4885SLC29A1 551/4885 |
| US-20240158431-A1 | COMPOSITIONS AND COMPOUNDS FOR CO-DELIVERY OF URIDINE AND KETOLEUCINE | CPT1B, UMPS, CKMT1A; CKMT1B | SLC28A1 826/4885SLC28A2 831/4885SLC29A1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.